REG - Danakali Limited - Issue of Equity and Total Voting Rights

DanakaliAnnouncement

21/12/2018 07:00

RNS Number : 1378L
Danakali Limited
21 December 2018
 





Announcement


Friday, 21 December 2018



 
Issue of equity and total voting rights
 
Danakali Limited (ASX: DNK / LSE: DNK) (Danakali, or the Company) advises that it has, conditional on admission, allotted and issued 8,571 new fully paid ordinary shares of no par value in the Company (Ordinary Shares) in lieu of fees to its corporate advisors.
 
Application has been made to the UK Listing Authority for the admission of those 8,571 new Ordinary Shares to the Official List of the UK Listing Authority and to trading on the London Stock Exchange's Main Market for listed securities and it is expected that dealings will commence on 4 January 2019. The new Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares in issue.
 
Following admission, the Company will have in issue a total of 264,422,398 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury.
 
Therefore, the total number of voting rights in the Company is 264,422,398 which may be used by shareholders or other persons as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
 
 
For more information, please contact:
 



Danakali


 




Seamus Cornelius
Executive Chairman
+61 8 6315 1444


William Sandover
Head of Corporate Development & External Affairs
+61 499 776 998




 
Corporate Broker - Numis Securities


 
UK IR/PR - Instinctif Partners




John Prior / Matthew Hasson / James Black /
Paul Gillam
+44 (0)20 7260 1000


David Simonson / George Yeomans /
Sarah Hourahane
danakali@instinctif.com
+44 (0)207 457 2020



 
 
 
- - - ENDS - - -




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFBLFLVLFFFBK